Story perspectives
FDA Review Sparks Concerns Over Mifepristone Access
9/25/2025
38 7
1 of 1
Story summary
- The U.S. Food and Drug Administration (FDA) is reviewing mifepristone's safety and efficacy, raising access concerns for abortion-rights advocates.
- Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary urged an investigation in a letter to Republican attorneys general.
- Telehealth now accounts for 14% of abortions in 2024, up from 10% in 2023, reflecting expanded access.
